Senseonics Holdings
Market Cap
US$95.2m
Last Updated
2020/07/15 00:00 UTC
Data Sources
Company Financials +
Executive Summary
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Limited growth with weak fundamentals.
Similar Companies
Share Price & News
How has Senseonics Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SENS's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
7.0%
SENS
2.0%
US Medical Equipment
1.5%
US Market
1 Year Return
-67.6%
SENS
9.2%
US Medical Equipment
6.9%
US Market
Return vs Industry: SENS underperformed the US Medical Equipment industry which returned 5.9% over the past year.
Return vs Market: SENS underperformed the US Market which returned 5.3% over the past year.
Shareholder returns
| SENS | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.0% | 2.0% | 1.5% |
| 30 Day | 4.5% | 6.0% | 5.9% |
| 90 Day | -37.6% | 10.2% | 17.9% |
| 1 Year | -67.6%-67.6% | 10.2%9.2% | 9.2%6.9% |
| 3 Year | -81.7%-81.7% | 57.4%53.1% | 36.4%27.5% |
| 5 Year | n/a | 104.6%88.6% | 64.9%47.0% |
Price Volatility Vs. Market
How volatile is Senseonics Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall St
Senseonics Holdings, Inc. Just Reported, And Analysts Assigned A US$1.22 Price Target4 months ago | Simply Wall St
Is Senseonics Holdings (NYSEMKT:SENS) Using Debt In A Risky Way?5 months ago | Simply Wall St
Need To Know: Senseonics Holdings, Inc. (NYSEMKT:SENS) Insiders Have Been Buying SharesValuation
Is Senseonics Holdings undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Senseonics Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Senseonics Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Take a look at our analysis of SENS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Senseonics Holdings regulatory filings.
- Explore potentially undervalued companies in the Healthcare industry.
Future Growth
How is Senseonics Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
9.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SENS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SENS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SENS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SENS's revenue (56.3% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: SENS's revenue (56.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SENS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Senseonics Holdings performed over the past 5 years?
-31.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SENS is currently unprofitable.
Growing Profit Margin: SENS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SENS is unprofitable, and losses have increased over the past 5 years at a rate of -31.4% per year.
Accelerating Growth: Unable to compare SENS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SENS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.4%).
Return on Equity
High ROE: SENS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is Senseonics Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: SENS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: SENS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: SENS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: SENS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SENS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SENS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 37.5% each year
Next Steps
Dividend
What is Senseonics Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SENS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SENS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SENS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SENS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SENS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.4yrs
Average management tenure
CEO
Tim Goodnow (58yo)
4.58yrs
Tenure
US$2,211,200
Compensation
Dr. Timothy T. Goodnow, also known as Tim, Ph.D., has been the Chief Executive Officer, President and Director of Senseonics Holdings, Inc. since December 2015. Dr. Goodnow served as the Chief Executive Of ...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD2.21M) is above average for companies of similar size in the US market ($USD618.98K).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.58yrs | US$2.21m | 0.19% $182.8k | |
| Chief Operating Officer | 3.5yrs | US$1.40m | 0.0013% $1.2k | |
| Chief Medical Officer & Director | 0.67yr | US$1.72m | 0.070% $67.1k | |
| CFO, Secretary & Treasurer | 0.67yr | no data | no data |
2.4yrs
Average Tenure
52.5yo
Average Age
Experienced Management: SENS's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.58yrs | US$2.21m | 0.19% $182.8k | |
| Chief Medical Officer & Director | 0.67yr | US$1.72m | 0.070% $67.1k | |
| Independent Non-Management Director | 4.58yrs | US$160.60k | no data | |
| Independent Non-Management Director | 4.58yrs | US$157.50k | 0.052% $49.5k | |
| Independent Chairman | 4.58yrs | US$181.63k | 0.38% $363.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Management Director | 3.83yrs | US$154.00k | 0.048% $45.3k | |
| Independent Non-Management Director | 4.58yrs | US$166.75k | 0.029% $27.1k | |
| Independent Non-Management Director | 4.58yrs | US$157.50k | 0.031% $29.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.6yrs
Average Tenure
62.5yo
Average Age
Experienced Board: SENS's board of directors are considered experienced (4.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.6%.
Top Shareholders
Company Information
Senseonics Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Senseonics Holdings, Inc.
- Ticker: SENS
- Exchange: AMEX
- Founded: 1996
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$95.222m
- Shares outstanding: 227.64m
- Website: https://www.senseonics.com
Number of Employees
Location
- Senseonics Holdings, Inc.
- 20451 Seneca Meadows Parkway
- Germantown
- Maryland
- 20876
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SENS | AMEX (NYSE MKT LLC) | Yes | New Common Stock | US | USD | Dec 2015 |
| 6L6 | DB (Deutsche Boerse AG) | Yes | New Common Stock | DE | EUR | Dec 2015 |
Biography
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes for a period of up to 90 and 180 days. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/15 00:00 |
| End of Day Share Price | 2020/07/14 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.